GLP-1 Weight Loss Without Insurance: How a Cash-Pay Program Is Priced

It is not that insurers doubt GLP-1 medications work. It is that most plans draw a hard line between covering a drug for diabetes and covering the same class of drug for weight loss, and that line is a cost decision, not a medical one.

Among larger employers, the gap is wide. In KFF's 2025 Employer Health Benefits Survey, only about one in five large employers (firms with 200 or more workers) covered GLP-1 medication specifically for weight loss, even though coverage for diabetes is far more common. Even among the biggest employers, those with 5,000 or more workers, only 43% covered it for weight loss, up from the year before but still less than half.

Cost is the reason employers give directly. Surveyed employers told KFF that GLP-1 spending had jumped to the top of their prescription drug budget within a year or two, in some cases doubling annually, and a number of employers that did offer coverage said they were now restricting it to employees with a diabetes diagnosis rather than weight loss alone.

Medicaid shows the same pattern from a different angle. Coverage of GLP-1 drugs for diabetes and several other FDA-approved uses is required of state Medicaid programs, but coverage for obesity specifically is optional, left to each state. As of January 2026, only 13 state Medicaid programs covered GLP-1 medication for obesity under their standard fee-for-service benefit.

Traditional Medicare does not cover GLP-1 medication for weight loss either; federal law has historically barred Medicare from covering any drug used for weight loss specifically. A temporary demonstration, the Medicare GLP-1 Bridge program, is covering GLP-1 medication for weight reduction for eligible Part D enrollees who meet its BMI criteria from July through December 2026 at a $50 copay, but it is a time-limited pilot, not a change to the underlying law.

It is easy to read "insurance doesn't cover this" as "this isn't real medicine." That is not what is happening here. Insurance coverage reflects a payer's cost calculation, built around its own enrolled population and budget cycle, not a judgment from the FDA or from the physicians who prescribe the medication.

That gap is exactly why a growing share of people pursuing medically supervised weight loss, including GLP-1 therapy where a physician determines it is appropriate, pay for the program directly rather than waiting on a coverage decision that may never come. A cash-pay structure means the price is set upfront and does not depend on a plan's formulary, a prior authorization, or a benefit year.

Our medical weight loss program in Ellicott City is priced the same way regardless of what any insurance plan would or would not have covered: in writing, upfront, month to month, with no contract.

Every program starts with a metabolic evaluation: a physician visit with a full health history, a metabolic panel with its lab fees included, a body composition scan, and a written plan. That evaluation is $299, or $249 through our new patient offer through November 30, and if you start a program within 30 days of your plan review, that amount is credited to your first month.

From there, two program structures cover ongoing care. The physician-supervised program is $199 a month and includes physician visits, prescription management, and ongoing dose adjustments, with any medication paid separately from that fee. The all-inclusive program is $449 or $599 a month, depending on which medication a physician prescribes, and folds the medication itself into that single monthly fee at any dose.

Nothing here runs through insurance. The program is cash pay only for the visits, the plan, and the medication, which is also why the price does not change based on a formulary tier or a denied prior authorization. Your physician confirms your exact total in writing before anything begins.

The metabolic evaluation is where a physician reviews your labs, body composition, and health history and decides whether medication belongs in your plan at all, not just which one. Nutrition, strength-preserving guidance, and monitoring are part of every program whether or not medication ends up being appropriate for you.

Paying out of pocket changes who is deciding the price. It does not change the medical judgment behind the plan: that still comes from a physician looking at your evaluation, not from a payer's cost target.

The clinic is about 12 minutes from Columbia Town Center via US-29, roughly 6.4 miles, close enough that the drive shouldn't be the reason a Columbia patient puts off asking about cost. Consultations start by video or phone, so you can ask directly how the program is priced and whether it fits your situation before scheduling anything in person.

That first conversation is also the place to ask what your evaluation and any ongoing program would actually total for you, since your physician confirms your specific number in writing rather than leaving you to estimate from a general price list.

A cash-pay program is a real monthly commitment, and it is reasonable to weigh it against other priorities before starting. What it buys you that an uncertain insurance process often cannot is a fixed, known price from the first conversation, without a prior authorization that can be denied, delayed, or reversed mid-year.

If you are still deciding whether a supervised program is the right next step, take the two-minute quiz for a starting point before your consultation, or read more about how the full program works from evaluation through maintenance, including how semaglutide and tirzepatide compare when a physician is choosing between them.